Antibody-drug conjugates—a new wave of cancer drugs

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• Antibody-drug conjugates (ADCs) are designed to target cancer cells by linking cytotoxic drugs to monoclonal antibodies.
• This approach aims to enhance therapeutic efficacy while minimizing systemic toxicity in cancer patients.
• Proof-of-concept has been established for ADCs using various cytotoxic payloads like calicheamicin, auristatin, and maytansine.

Purpose of the Study:

• To review the characteristics of established cytotoxic drug platforms used in ADCs.
• To examine the chemical conjugation strategies employed for developing ADCs.
• To provide an overview of the current landscape of ADC technology.

Main Methods:

• Literature review of scientific articles and clinical trial data.
• Analysis of chemical structures and conjugation techniques for ADC payloads.
• Synthesis of information on efficacy and toxicity profiles of existing ADCs.

Main Results:

• Several cytotoxic payloads (calicheamicin, auristatins, maytansinoids) have demonstrated feasibility in ADC development.
• Various chemical conjugation methods are available, impacting ADC stability and drug release.
• While promising, challenges remain in optimizing target specificity and managing on-target toxicities.

Conclusions:

• ADCs represent a significant advancement in targeted cancer therapy.
• Understanding cytotoxic payload characteristics and conjugation chemistry is crucial for ADC design.
• Further research is needed to fully elucidate ADC efficacy and refine safety profiles.